JP2024540673A - 関節リウマチの治療 - Google Patents

関節リウマチの治療 Download PDF

Info

Publication number
JP2024540673A
JP2024540673A JP2024531608A JP2024531608A JP2024540673A JP 2024540673 A JP2024540673 A JP 2024540673A JP 2024531608 A JP2024531608 A JP 2024531608A JP 2024531608 A JP2024531608 A JP 2024531608A JP 2024540673 A JP2024540673 A JP 2024540673A
Authority
JP
Japan
Prior art keywords
compound
acid
kit
combination
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540673A5 (cg-RX-API-DMAC7.html
Inventor
エンゲルブレヒト ノルドキルド ヨナセン,トーマス
Original Assignee
シナクト ファーマ エーピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シナクト ファーマ エーピーエス filed Critical シナクト ファーマ エーピーエス
Publication of JP2024540673A publication Critical patent/JP2024540673A/ja
Publication of JP2024540673A5 publication Critical patent/JP2024540673A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024531608A 2021-11-29 2022-11-29 関節リウマチの治療 Pending JP2024540673A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21211179 2021-11-29
EP21211179.3 2021-11-29
PCT/EP2022/083624 WO2023094692A1 (en) 2021-11-29 2022-11-29 Treatment of rheumatoid arthritis

Publications (2)

Publication Number Publication Date
JP2024540673A true JP2024540673A (ja) 2024-10-31
JP2024540673A5 JP2024540673A5 (cg-RX-API-DMAC7.html) 2025-12-08

Family

ID=78821593

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531608A Pending JP2024540673A (ja) 2021-11-29 2022-11-29 関節リウマチの治療

Country Status (5)

Country Link
US (1) US20250032449A1 (cg-RX-API-DMAC7.html)
EP (1) EP4440572A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024540673A (cg-RX-API-DMAC7.html)
CN (1) CN118613260A (cg-RX-API-DMAC7.html)
WO (1) WO2023094692A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024398488A1 (en) * 2023-12-11 2026-06-04 Synact Pharma Aps Treatment of subpopulation of patients with rheumatoid arthritis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE059638T2 (hu) * 2019-05-10 2022-12-28 Synact Pharma Aps Ízületi gyulladásos betegségek kombinált kezelése

Also Published As

Publication number Publication date
US20250032449A1 (en) 2025-01-30
EP4440572A1 (en) 2024-10-09
WO2023094692A1 (en) 2023-06-01
CN118613260A (zh) 2024-09-06

Similar Documents

Publication Publication Date Title
EP3773558B1 (en) Combination treatment of arthritic disease
US8784812B2 (en) Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
Nakashima et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate
JP2017128578A (ja) 腎疾患の治療におけるモノおよびジカルボン酸のアミドの使用
WO2023094692A1 (en) Treatment of rheumatoid arthritis
RU2322238C2 (ru) Лечение ревматоидного артрита
RU2828044C2 (ru) Комбинированное лечение артрита
HK40047132A (en) Combination treatment of arthritic disease
HK40047132B (en) Combination treatment of arthritic disease
WO2025124760A1 (en) Treatment of subpopulation of patients with rheumatoid arthritis
US20250302804A1 (en) Resomelagon and its derivatives for the treatment of cardiovascular disease, hypertension and atherosclerosis
CA2577883A1 (en) Tnf-binding protein-1 in the treatment of psoriasis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251128